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1. Introduction
Four key milestones have to be realized for the ideal customized stem cell therapy to be
successful. First, stem cells utilized in these therapies have to be genetically stable and
epigenetically regulated to ensure the safety of stem cells employed in any future therapies.
This is essential to ensure that patients undergoing stem cell therapy are not exposed to
increased risks of tumorigenesis and other mutagenic diseases. Second, stem cells should be
able to evade the innate immune response of patients, possibly via the secretion of immuno‐
suppressive molecules that inhibit immune responses or by displaying host cellular recogni‐
tion markers. The survival of transplanted stem cells is crucial for the design of an effective
therapy. Additionally the ability of transplanted stem cells to evade immune detection and
inflammatory responses will prevent undesired symptoms such as graft-versus-host-disease
in patients. Third, stem cells employed in these therapies should be location specific. These
stem cells should possess specific homing cell surface markers that will allow them to locate
and migrate to specific localities. This will ensure that stem cells used in therapies will only
accumulate in diseased tissues for targeted therapeutic effect, and not in other healthy regions
where detrimental non-specific interactions might occur. Finally, the stem cells used in these
therapies should be functionally specific and disease relevant. Transplanted stem cells should
be designed to restore a healthy phenotype in patients. These cells should be able to restore
organ and tissue function in regenerative therapies, either directly by replicating to replace
damaged portions of these organs and tissues and/or indirectly by secreting therapeutic
molecules to mediate their functional restoration. These stem cells should also be epigenetically
primed for specific functions to ensure that they are able to reverse the effects of treated
diseases while minimizing unwanted side effects.
Stem cells are commonly classified into three broad categories based on how they were
derived. Embryonic stem cells (ESCs) are stem cells that are isolated from the inner cell mass
of the early developing embryo. Adult stem cells assist in the natural regeneration and repair
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in developed organisms and can be purified from their tissues. Induced pluripotent stem cells
(iPSCs) are artificially derived stem cells that are formed via various genetic and epigenetic
reprogramming procedures. Of the three broad categories of stem cells, adult stem cells are
most widely utilized in clinical trials and experimental therapies worldwide. Most adult stem
cells are multipotent and differentiate to form only a limited subset of cell types. Hence these
stem cells are commonly classified according to their developmental commitment or tissue
source. Examples of adult stem cells include mesenchymal stem cells (MSCs), neural stem cells
(NSCs), hematopoietic stem cells, inner ear stem cells, mammary stem cells, endothelial stem
cells, intestinal stem cells, and testicular stem cells.
Adult stem cells present the first success of human experimental stem cell therapy. There are
several reasons why adult stem cells therapies are currently more successful than ESC and
iPSC therapies. Firstly, stem cell therapies involving adult stem cells are often autotransplants
with minimal potential for immune rejection. These adult stem cells can be harvested directly
from individual patients before being utilized as transplants. Hence these adult stem cells will
exhibit host cell recognition molecules unlike ESCs and iPSCs that may provoke an immune
response when used in therapies. Secondly since most adult stem cells therapies involve
minimally processed cells, there a reduced possibility of genetic mutation or chromosome
aberration occurring compared to ESCs and iPSCs that have to be cultured extensively in vitro
before their use in therapies. Thirdly, adult stem cells do not readily form tumors when
introduced into patients and are considered to be safer than ESCs and iPSCs that display
greater carcinogenic potential. Finally, the use of adult stem cells in therapies is not considered
to be controversial as they can be readily extracted from patient tissues and do not require the
destruction of embryos to derive stable cell lines unlike ESCs. These key advantages of adult
stem cells have led to their wider utilization in research and various clinical trials compared
to ESCs and iPSCs.
2. Mesenchymal stem cell therapy
Mesenchymal stem cells (MSCs) are one of the first multipotent adult stem cells to be utilized
in stem cell therapies. These stem cells have the ability to differentiate and form bone, cartilage,
and adipose tissues. While the bone marrow is the most common source of MSCs for thera‐
peutic purposes, they can also be found in adipose and synovial tissue, skeletal muscles,
peripheral blood, breast milk, and the umbilical cord [1, 2].
While these stem cells are commonly referred to as MSCs, they actually form a heterogeneous
population of cells as evidenced by differences in proliferative capacity, differentiation
potential, cellular markers, and morphology. For example, MSCs derived from the bone
marrow (M-MSC) have lower proliferative capacity, followed by adipose tissue MSCs (A-
MSC) and umbilical cord blood MSCs (U-MSC) which have the highest proliferative capacity
[3]. MSCs also have differing differential potentials. For example, bone marrows MSCs have
a higher chondrogenic potential while adipose MSCs have a lower chondrogenic potential [4,
5]. In addition both bone marrow and adipose MSCs readily form cells with adipogenic
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phenotypes unlike umbilical cord blood MSC that display a lower capacity to form adipocytes
[3, 6]. MSCs also express different cellular markers. For example A-MSCs express CD34,
CD49d, and CD54 at higher levels than M-MSCs while M-MSCs and U-MSCs express higher
levels of CD 106 than A-MSCs [7]. M-MSCs and A-MSCs also have higher levels of CD90 and
CD105 expression when compared to U-MSCs [3]. The morphology of MSCs can also differ
significantly and even MSCs from the same source display heterogeneous morphologies.
Various descriptions of MSCs in the literature include spindle shaped, round, fibroblastoid
cells, flattened cells, and blanket cells [8, 9]. Further studies to understand these inherent
differences in various subpopulations of MSCs could lead to an improved understanding of
how epigenetic differences regulate stem cell differentiation fates, homing to specific recog‐
nition sites, proliferation rates, and senescence.
M-MSCs are currently the most widely used stem cells in clinical trials and therapies. Both
autograft and allograft M-MSCs have been extensively tested for their therapeutic safety and
effectiveness in alleviating the symptoms of several diseases. One of the key reasons for the
success of M-MSCs therapy is because these cells possess intrinsic immunomodulatory
properties that enable M-MSCs to inhibit and evade potential immune rejection when
transplanted [10]. M-MSCs are able to inhibit the maturation and function of various immune
cells including dendritic cells, natural killer cells, B cells, and T lymphocytes [11]. Additionally
M-MSCs have reduced immunogenicity due to their minimal expression of surface MHC ІІ
proteins and the lack of T cell stimulatory proteins like CD80 and CD86 [12]. Another important
reason for the early success of M-MSCs based therapies is that MSCs have low tumorigenic
potential and are safer than therapies based on ESCs or iPSCs which display robust tumori‐
genicity [13].
Due to these intrinsic advantages of MSCs, clinical trials can be conducted to evaluate their
safety and effectiveness in treating various diseases. For example, the safety and effectiveness
of M-MSC transplantation for joint cartilage repair has been evaluated in several studies. In a
clinical trial involving 41 patients studied over a period of between 5 to 137 months, M-MSC
transplantation did not contribute to increased risk of tumors or infection [14]. Another study
has reported the potential for M-MSC regenerative knee therapy to induce cartilage and
meniscus growth and increase range of motion [15]. These results are supported in a larger
scale M-MSC transplantation study involving 339 patients which reported no increased risk
of tumor formation and a significant improvement of knee function in transplant patients [16].
While further clinical trials have to be conducted to verify these preliminary results, the
successes of these initial clinical trials indicate that M-MSC therapy is likely to be safe and can
catalyze cartilage repair.
The effectiveness of M-MSC and other MSC therapies for various autoimmune diseases has
also been studied in several small clinical trials. These autoimmune diseases include multiple
sclerosis, Crohn’s disease, scleroderma, and systemic lupus erythematosus [17]. The causes of
many of these autoimmune diseases are not well understood and it is likely that while the
patients suffer from similar symptoms, contributing disease factors may vary significantly
between patients. However the application of a generic MSC transplantation therapy was
successful in alleviating the symptoms of these patients in several clinical trials.
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Multiple sclerosis is a debilitating autoimmune disease caused by immune mediated damage
of neural myelin sheath. Progressive neural damage results in many disabling symptoms
including the loss of balance, vision and memory. M-MSC clinical trials for multiple sclerosis
therapy have provided limited preliminary data indicating that M-MSC transplantation is safe,
inhibits the progress of multiple sclerosis through immune regulated neuroprotection, and can
repair limited damage to the CNS [18, 19]. For example, in a preliminary phase 2 clinical trial
involving 10 patients diagnosed with progressive multiple sclerosis, autologous infusion of
externally expanded M-MSCs was shown to improve visual acuity and increase optic nerve
area without any major side-effects [18].
Crohn’s disease is a chronic autoimmune bowel disease characterized by inflammation of the
gastrointestinal tract. In severe cases, this uncontrolled immune response may result in
infection, hemorrhage, and intestinal fistulas. M-MSC clinical trials involving patients
suffering from Crohn’s disease have sought to harness the innate immunomodulatory capacity
of MSCs to mitigate abnormal immune response in these patients and determine the safety of
any potential therapies. In two phase one clinical trials a total of 22 adult Crohn’s disease
patients were enrolled to investigate the effects of M-MSC therapy. In the first trial it was
determined that while autologous M-MSC infusion therapy did not result in adverse side
effects, it only had a modest impact in alleviating the autoimmune response in these patients
[20]. In the second trial in vitro expanded M-MSCs were directly injected into the intestinal
wall and lumen [21]. When M-MSCs were directly injected, they were able to inhibit inflam‐
mation locally and mediate healing of intestinal tissue in these regions.
Scleroderma is an autoimmune connective tissue disorder characterized by accumulation of
collagen in the skin, heart, kidneys or lungs. This buildup of collagen may lead to skin ulcers,
pulmonary fibrosis, heart and kidney failure. Exploratory M-MSC clinical trials involving
patients suffering from Scleroderma have sought to harness the regenerative and immuno‐
modulatory capacity of MSCs to initiate ulcer healing and prevent organ failure while
evaluating the safety of these therapies. In two separate phase one clinical trials a total of 7
adult scleroderma patients were enrolled to determine the effects of M-MSC therapy. In the
first trial allogeneic transplantation of donor M-MSC was performed via intravenous infusion
and was associated with possible pericardial calcification and increased risk of cardiac
impairment. While patients in this trial displayed a slight improvement in MRSS score and
healing of skin ulcers, the effects were on occasion only temporary and the disease regressed
in some patients [22]. The second trial involved autologous transplantation of either M-MSC
or peripheral stem cells in patients via intramuscular injection [23]. This local stem cell therapy
was able to induce healing of skin ulcers in these patients and improved endothelial function
of blood vessels.
Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder that can affect the
kidney, lung, brain, and other organs. Severe SLE may result in kidney failure, stroke, and
inflammation of blood vessels. M-MSC clinical trials in SLE patients have attempted to treat
progression of SLE symptoms by harnessing the immunomodulatory properties of MSCs. In
two clinical trials a total of 19 patients suffering from SLE were treated with M-MSC transplants
to determine if MSC therapy is safe and effective in reversing the symptoms of SLE patients.
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In the first clinical trial SLE patients were treated with allogeneic M-MSC infusion [24].
Treatment with donor M-MSCs was shown to restore kidney function and reverse the
progression of SLE. The second clinical trial involved a larger group of patients and provided
additional evidence that M-MSC therapy could mitigate the symptoms of SLE in patients [25].
Other studies have also attempted to verify the effectiveness of M-MSC therapies for various
diseases. M-MSC therapy has been shown to improve liver function in patients suffering from
liver cirrhosis by encouraging hepatocyte proliferation [26]. The co-transplantation of M-MSCs
and kidney transplants for patients with kidney failure can reduce the risk of acute transplant
rejection and improve transplant function in treated patients [27]. M-MSC therapy can also
catalyze functional recovery and improve survival rates in ischemic stroke patients [28, 29].
These clinical studies provide preliminary evidence that M-MSC therapy is safe and the
regenerative properties of these stem cells can be harnessed to treat a wide variety of diseases.
To develop the ideal next generation stem cell therapy, it is necessary to evaluate currently
available therapies to identify their current limitations and suggest areas for improvement.
Next generation stem cell therapies will have to fulfill the four key milestones (safety, immune
evasion, location specificity, and disease relevancy) of customized stem cell therapy. Human
M-MSC therapy has been extensively studied in multiple experiments and clinical trials and
is an ideal candidate for evaluation against these key milestones.
Firstly the safety of M-MSC therapies must be considered. Multiple clinical trials mentioned
previously involving the infusion and injection of both autologous and allogeneic M-MSCs for
therapeutic purposes stated that patients were generally not exposed to increased risks of
cancer or other serious side-effects. However, a study stated that the infusion of M-MSC may
lead to pericardial calcification and increased risk of cardiac impairment in some patients [22].
As currently completed clinical trials often only involve a relatively small patient population
or are only conducted over a brief period of time, the risks of M-MSC therapies may not be
fully understood and more studies have to be conducted to ensure that the benefits of these
therapies outweigh their potential risks. Another source of concern is the use of in vitro
cultured M-MSCs in therapies. M-MSCs exist naturally in low concentrations in the human
bone marrow, and often have to be concentrated and expanded in vitro media to provide
sufficient numbers of stem cells for therapeutic purposes. This process may expose M-MSCs
to xenogeneic antigens such as in fetal calf serum in the media. Culture of M-MSCs in vitro
also exposes cells to an atmospheric oxygen concentration of 21% that is radically different
from physiological conditions of 1-7% [30]. These in vitro culture conditions may affect the
genetic and epigenetic stability of these stem cells resulting in an increased chance of muta‐
genesis. In an effort to resolve these potential issues, several studies have attempted to identify
the ideal M-MSC culture media. From these studies, it has been proposed that human platelet
lysate can be used as a viable substitute to fetal calf serum to reduce unnecessary exposure to
xenogeneic antigens [31]. M-MSCs should also be cultured in low oxygen concentrations of
approximately 3% to reduce oxidative stress and telomere shortening and increase the
proliferative lifespan and genetic stability of in vitro M-MSCs [32]. The implementation of
these protocols will provide M-MSCs with culture conditions that are more similar to the M-
MSC native environment and minimize the impact of in vitro expansion on the genetic and
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epigenetic stability of M-MSCs. In conclusion, while some doubts about the safety of M-MSC
based therapies remain, various clinical trials and experiments have indicated that the use of
minimally expanded M-MSCs is relatively safe for patients, especially when coupled with the
latest M-MSC expansion protocols.
Secondly the ability of M-MSCs to evade immune detection must be accessed. No incidents of
acute immune rejection were reported in the various clinical trials involving autologous and
allogeneic transplants of M-MSCs. This could possibly be attributed to the fact that autologous
M-MSCs are extracted from the treated patients and present host cellular recognition markers.
Additionally M-MSCs have reduced immunogenicity due to the naturally low expression
levels of surface MHC ІІ proteins and the lack of other T cell stimulatory proteins like CD80
and CD 86 in M-MSCs. The multifaceted immunomodulatory capacity of M-MSCs must also
be considered. Various studies have indicated that M-MSCs are able to inhibit the proliferation
of T lymphocytes possibly via the activation of regulatory T cells and secretion of immuno‐
suppressive factors like transforming growth factor beta1 and hepatocyte growth factor
[33-35]. The inhibition of T lymphocytes that are essential for the recognition and destruction
of foreign transplants contributes to the ability of M-MSCs to evade immune detection. M-
MSCs can also interfere with the development and function of antigen-presenting dendritic
cells. Soluble factors secreted by M-MSCs can inhibit differentiation of monocytes to dendritic
cells and suppress the production of cytokines [36]. M-MSCs can also affect the function of
mature dendritic cells by suppressing the expression of various presentation and co-stimula‐
tory molecules like CD1a, CD80, CD83, and CD86 [37]. This impedes dendritic cells from
inducing T cells and B cells and prevents resistance of foreign transplants from developing.
Finally M-MSCs can also inhibit the proliferation of B cells stimulated with anti-CD40
monoclonal antibody and IL-4 by halting the G0/G1 cell cycle phase [38, 39]. The data from
these studies indicate that M-MSCs are able to efficiently evade the innate immune response
of patients via various mechanisms of cellular recognition and immunosuppression.
Thirdly the location specificity of M-MSCs employed in various therapies should be consid‐
ered. While M-MSC clinical trials discussed previously indicate that M-MSC therapy is able
to alleviate the conditions of various autoimmune diseases and induce cartilage repair,
infusion of M-MSCs resulted in non-specific distribution of these cells within the patient. Non-
specific infusion of M-MSCs resulted in a distribution of these cells in various organs including
the heart muscle, liver, kidney, skin, and lung. This may result in undesirable side-effects such
as pericardial calcification and increased risk of cardiac impairment in patients as described
in a clinical study [22]. Hence further research is required to design a stem cell therapy that is
more specific to the injury location. In the ideal therapy, stem cells could be engineered with
receptors for mobilization to the location of injury. Alternatively, stem cells could be integrated
within a scaffold that would then be implanted into patients to improve the specificity of these
therapies. The direct injection of M-MSCs near sites of injury may also provide increased
specificity to these therapies.
The fourth consideration is stem cells utilized in these therapies should be disease relevant.
Disease relevant stem cells should be epigenetically primed to treat specific underlying causes
of disease in each patient. M-MSCs utilized in these clinical trials are not disease relevant and
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cure or alleviate various disease symptoms through their general immunomodulatory and
regenerative properties. While non-specific M-MSCs may still be a viable therapy for a wide
range of diseases, the lack of specificity in these therapies may result in potentially lethal
consequences. For example, the general immunosuppressive properties of M-MSCs can
increase the severity of breast cancer by increasing the concentration of regulatory T cells and
inhibiting the innate immune response against cancer cells [35, 40]. M-MSCs could also secrete
soluble factors that accelerate tumor growth, such as through the activation of the phosphati‐
dylinositol-3-kinase/Akt signaling pathway which can prevent apoptosis and induce prolif‐
eration of cancer cells [41]. Hence additional studies have to be performed to understand how
stem cells can be epigenetically reprogrammed to enhance their specificity for disease treat‐
ment and reduce undesirable side effects.
In conclusion, it can be seen that while current clinical data demonstrates that M-MSC based
therapies are relatively safe and M-MSC transplants can evade immune detection and survive
in patients, these therapies rely on the general immunosuppressive and regenerative proper‐
ties of M-MSCs and are neither specific nor disease relevant. Hence although the utilization of
M-MSC based therapies may potentially result in cures for various diseases, more research is
necessary for developing the ideal stem cell therapy.
3. Other MSC and adult stem cell therapies
While the bone marrow is the most commonly mentioned source of MSCs, MSCs can also be
extracted from other sources including adipose and synovial tissue, skeletal muscles, periph‐
eral blood, breast milk, and the umbilical cord [1, 2]. In particular, adipose MSCs (A-MSCs)
have been increasingly studied because these cells can be readily purified from adipose tissue
via liposuction and is a relatively non-invasive procedure compared to bone marrow extraction
of M-MSCs [42, 43]. A-MSCs have similar immunomodulatory effects compared to M-MSCs
and can be utilized for treatment of similar diseases such as scleroderma [44, 45]. A-MSCs also
possess a similar capacity to regenerate cartilage and bone tissues and mediate some symptoms
in patients with osteonecrosis and osteoarthritis [46]. Hence the discovery of A-MSCs provides
patients with an alternative source of MSCs in the event that they are unable to undergo M-
MSC extraction.
MSCs are also present in human and animal synovial fluid. These synovial MSCs (S-MSCs)
have a greater ability to proliferate and differentiate compared to other MSCs and can form
osteoblasts, adipocytes, chondrocytes, and neurons [47, 48]. S-MSCs also possess greater
cartilage regenerative potential than other MSCs with 60% of S-MSCs placed on cartilage
defects attaching to the defect within 10 minutes [49]. S-MSCs posses similar regenerative
potential as M-MSCs and can also initiate regeneration of the nucleus pulposus in the damaged
rabbit intervertebral disc by suppressing inflammation and inducing the synthesis of type ІІ
collagen which acts as a supportive framework for nucleus pulposus repair [50]. In addition
S-MSCs can be readily harvested via punch biopsy [9]. The greater innate proliferative ability
of S-MSCs and the relative ease of obtaining S-MSCs indicate that it may be an excellent source
of MSCs for future regenerative therapies
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Neural Stem Cells (NSCs) have also been studied in an attempt to harness their regenerative
potential for therapeutic purposes. NSCs can be found in various tissues including the bone
marrow and striatum [51, 52] and their regenerative properties have been assessed by both
NSC transplantation and endogenous NSC functional studies. NSCs can initiate axon remye‐
lination, neuroprotection, proliferation of oligodendrocyte progenitors, and functional
recovery when transplanted into mice experimental autoimmune encephalomyelitis (EAE)
models of multiple sclerosis [53]. NSCs also possess similar immunomodulatory properties as
MSCs. For example, NSCs can inhibit dendritic cell and antigen-specific T cell maturation
through the release of morphogens such as bone morphogenetic protein 4 [54]. Additionally,
NSCs can suppress T-cell proliferation through the release of prostaglandin E2 and nitric oxide
[55]. This innate immunomodulatory property of NSCs has been harnessed to induce stable
pancreatic islet graft function in mice, without the need for long-term immunosuppression
[56]. The immunosuppressive potential of NSC can also be enhanced by engineering NSCs to
produce anti-inflammatory cytokines such as IL-10 [57]. Engineered NSC transplants have
greater therapeutic potential than ordinary NSCs and give rise to enhanced functional recovery
of EAE mice.
Functional studies of endogenous NSCs have revealed the complex regulatory pathways
governing in vivo neuronal regeneration. While neural stem cell niches exist in the subven‐
tricular zone and the subgranular zone of the hippocampal dentate gyrus [58], NSCs in these
niches are unable to initiate spontaneous neural regeneration in many diseases. Hence recent
research has been concerned with elucidating the regulators of neurogenesis and repair. For
example neurogenesis can be initiated by suppressing Olig2 resulting in increased neurogen‐
esis for brain injury repair [59]. Other molecular regulators of neurogenesis include morpho‐
gens like Shh and Wnt, transcription factors like Sox2, growth factors like Fibroblast Growth
Factor family, and cell surface molecules like Notch1 [60]. An improved understanding of the
molecular pathways that regulate the differentiation, mobilization, and proliferation of
endogenous NSCs and the development of molecular tools to manipulate these pathways may
lead to the development of novel minimally invasive regenerative therapies.
Other adult stem cells that have been evaluated for therapeutic use include hematopoietic stem
cells, inner ear stem cells, mammary stem cells, intestinal stem cells, and adult germline stem
cells. Hematopoietic stem cells are multipotent and can form various blood cells such as those
from the lymphoid and myeloid lineages. Allogeneic hematopoietic stem cell transplantation
(HSCT) therapy in leukemia patients can lead to remission by inducing an immune antitumor
response [61]. HSCT has also been utilized to cure other diseases including sickle cell anemia,
acquired aplastic anemia and thalassemia [62, 63]. HSCT can also halt neurological deteriora‐
tion in X-linked adrenoleukodystrophy patients [64]. HSCT is also useful for alleviating
symptoms of Hurler Syndrome and other lysosomal storage diseases and these grafts can
replace metabolic enzymes that are lacking in host cells.
Inner ear stem cells are important progenitors of auditory hair cells and exist endogenously
in both the utricular sensory epithelium and the dorsal epithelium of the cochlear canal [65,
66]. An improved understanding of molecular regulatory pathways in these stem cells could
lead to the development of regenerative therapies for treating hearing impairment. Ongoing
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studies have revealed that the over-expression of SKP2 can induce proliferation of non-sensory
cells that can differentiate to form hair cells through the co-expression of Atoh1 [67]. Develop‐
mental studies have also provided insight into the Notch signaling pathway, and its influence
on the lateral-inhibition mediation differentiation of hair cells [68, 69]. Further studies could
lead to the development of a viable stem cell therapy for regenerating auditory hair cells and
a cure for hearing impairment.
Mammary stem cells are indispensible in the formation of mammary glands and can possess
the capacity to form myoepithelial cells, alveolar epithelial cells, and ductal epithelial cells [70,
71]. The deregulation of various signaling pathways including the Notch, Wnt, and Hedgehog
pathways in mammary stem cells has been implicated in breast cancer development [71, 72].
These studies could lead to the development of anti-cancer drugs that target specific signaling
pathways.
Intestinal stem cells are multipotent progenitors of the intestinal epithelial cell lineages. Studies
of intestinal stem cells have revealed the role of the Notch and Wnt signaling pathways in
intestinal stem cell maintenance, differentiation, and proliferation and how deregulation of
these pathways can promote intestinal carcinogenesis [73, 74]. An impaired differential
capacity of intestinal stem cells has also been linked to inflammatory bowel diseases like
Crohn’s disease and ulcerative colitis [75]. Future studies based on these discoveries could lead
to more effective cures for these diseases.
Adult germline stem cells are essential for gamete generation and can be derived from testis
spermatogonial cells. These stem cells are pluripotent and share characteristics similar to ESCs
[76]. The pluripotent nature of these stem cells may allow the development of regenerative
therapies not possible with other multipotent adult stem cells. Adult germline stem cell
transplantation can also be utilized for fertility restoration in animals [77-79]. This regenerative
ability could be utilized for maintaining the fertility of patients undergoing radiotherapy,
chemotherapy and other therapies that may cause infertility.
A comparison to determine how epigenetic differences inherent to these different classes of
adult stem cells lead to a wide variation in differentiation, homing, proliferation, and immu‐
nomodulation capacities will enable the design of novel stem cell therapies for specific
diseases. The differentiation potentials of adult stem cells can vary widely, for instance
hematopoietic stem cells tend to form cells from the lymphoid and myeloid lineages, while
neural stem cells tend to form neural cells like neurons, oligodendrocytes and astrocytes.
Differences in differential predisposition also exist within a similar class of stem cells. A-MSCs
tend to form adipocytes and cardiomyocytes, while M-MSCs form chondrocytes more readily
[4, 5]. Further studies to map epigenetic differences between these stem cell populations will
reveal how differentiation is regulated. This will lead to an improved ability to prime and select
optimal stem cell transplants for disease therapy. For example, a better understanding of
underlying pro-chondrogenic factors will enable the engineering of stem cells specialized in
cartilage regeneration. Detailed studies of other intra-population epigenetic variations will
also lead to better understanding of how these differences lead to differences in other prop‐
erties of stem cells and augment the safety, effectiveness, and specificity of stem cell therapies.
In conclusion, it can be seen that while the safety of adult stem cell therapies remains a key
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concern especially in the less studied stem cells, the innate immunomodulatory and regener‐
ative capacity of adult stem cells can be exploited for curing a wide range of diseases.
4. Induced pluripotent stem cells
The discovery of iPSCs has led to a revolution in stem cell research. The ability to reprogram
adult somatic cells to iPSCs using an increasing array of novel vectors and strategies has
opened up a myriad of possibilities for therapeutic stem cell development. iPSC based
therapies possess several advantages over adult stem cell and ESC based therapies. First, since
iPSCs can be derived from patients like adult stem cells, they will exhibit host cellular
recognition markers and can evade immune rejection more readily than ESCs. Additionally
since iPSC lines can be derived from patients, they do not face the ethical concerns associated
with ESC derivation. The use of iPSCs is also advantageous because iPSCs can be modified to
produce desired cell phenotypes that may not be naturally available in adult stem cell and ESC
populations. Hence iPSCs can be customized for treating specific diseases unlike other stem
cells whose curative properties tend to be more general.
However currently available iPSCs face several limitations that prevent their use in patient
therapies. First the iPSC derivation process commonly involves the use of viral vectors such
as lentiviral and retroviral vectors which results in the integration of viral DNA in iPSCs [80,
81]. Second, many iPSC derivation processes involve the over-expression or integration of
proto-oncogenes such as Oct4, c-Myc, and Sox2 [82-86]. Third, iPSC cultures are genetically
unstable and contain numerous genetic abnormalities including protein coding mutations,
copy number variations, and chromosomal aberrations [87-89]. Fourth, the iPSC reprogram‐
ming process may be incomplete and iPSCs can retain epigenetic memory from parental
somatic cells [90, 91]. Finally, the transformation efficiency of adult somatic cells to iPSCs is
inefficient (0.001% - 4.4%) and only a small fraction of adult somatic cells can be transformed
to iPSCs via existing methods.
These current shortcomings hinder the development of iPSCs suitable for patient therapy.
The  use  of  viral  reprogramming  vectors,  over-expression  of  proto-oncogenes,  and  sub-
optimal  culture  conditions  contribute  to  widespread  genetic  mutation  and  increased
tumorigenic potential in iPSCs. Consequently, iPSCs can readily form tumors in immune
deficient mice and mice derived from iPSCs have a high chance of developing tumors [82,
92]. To overcome these limitations, new methods for iPSC reprogramming were developed
to enhance the genetic integrity of iPSCs. Advances in reprogramming enabled the genera‐
tion of iPSCs without c-Myc and mice without tumors could be derived from these iPSCs
[93]. Additionally, non-integrating viral vectors like adenoviruses were used to prevent the
introduction of foreign viral DNA into iPSCs [94]. More recently iPSCs have been generat‐
ed via transfection of modified mRNA, this DNA free method results in a higher efficiency
of iPSC generation compared to previous methods and does not introduce any exogenous
DNA into reprogrammed cells  [95].  Optimized iPSC culture  and reprogramming condi‐
tions will also be essential for maintaining genetic stability and increasing transformation
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efficiency. High atmospheric oxygen concentration (~21%) exposes stem cells to increased
oxidative stress and DNA damage [32]. Lowering the oxygen concentration to 5% can improve
iPSC generation efficiency and genetic stability of stem cells [96]. The addition of vitamin C
and other antioxidants can also improve the efficiency of iPSC generation by preventing the
accumulation of reactive oxygen species and promoting epigenetic modifications required
for reprogramming to occur [97]. Reprogramming and iPSC culture maintenance also requires
precise manipulation of other medium conditions. iPSC progenitors have to be cultivated in
conditions that facilitate their survival but these original conditions may have to be modi‐
fied to enhance reprogramming efficiency and maintain iPSC populations [98, 99]. The search
for improving the efficiency of iPSC generation has also led to the use of miRNA sequen‐
ces in reprogramming. Viral  aided miR302/367  cell  reprogramming can reprogram fibro‐
blasts to iPSCs with up to 10% efficiency [100].
The reprogramming of adult somatic cells to ideal iPSCs will involve a complex epigenomic
transformation of the cellular epigenome to resemble ESC epigenetics. However iPSCs derived
with current procedures retain unique epigenetic signatures that differ from the ESC epige‐
nome. Some common epigenetic differences include variations in DNA methylation at CpG
islands and histone modifications [101, 102]. The epigenetic memory of iPSCs is an artifact
from the reprogramming process and parental cell epigenetics and can affect the differentiation
predisposition of iPSCs [90]. This iPSC epigenetic signature can also be transmitted to
successive generations of iPSCs and their differentiated progeny [102]. A failure to reset the
epigenetic memory of iPSCs to more closely resemble the epigenetic ground state of ESCs could
affect the function and safety of differentiated cells derived from these iPSC lines.
The issue of residual iPSC epigenetic memory can be partially addressed. For example, somatic
cell nuclear transfer has been proposed as a viable method for resetting epigenetic memory
[91]. Sodium butyrate, a short-chain fatty acid, could also assist in programming iPSCs closer
to the epigenetic ground state by inhibiting histone deacetylase, directing the acetylation of
specific genes, and encouraging stem cell renewal [103, 104]. DNA methyltransferase inhibitors
can also be used to direct DNA methylation at specific sites for more complete epigenetic
reprogramming [105]. The iPSC culture environment can also be manipulated to achieve a
desired epigenetic state. For example, reducing culture oxygen concentration to 2% can induce
epigenetic modifications that increase the expression of the retinal genes Six3 and Lhx2 in iPSCs
while an oxygen concentration of 5% can increase the efficiency of iPSC regeneration [96,
106]. However despite the increased availability of tools for epigenetic modification, more
studies are required to determine the ideal epigenomic ground state for therapeutic stem cells.
Comprehensive epigenetic mapping of ESCs and adult stem cells could provide important
clues and enable the development of improved experimental procedures for reprogramming
adult somatic cells to mirror this ideal epigenomic ground state.
When evaluated against the four key milestones, iPSCs are clearly inferior to M-MSCs and
other adult stem cells currently being evaluated in experimental therapies. First, iPSCs are
neither genetically nor epigenetically stable, this inherent property of iPSCs, along with the
integration of proto-oncogenes as a byproduct of some iPSC reprogramming procedures
results in increased propensity for tumorigenesis in vivo. Hence the safety of iPSC based
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therapies remains a key concern and must be resolved before they can be tested in clinical
therapies. Second, while iPSCs can be derived from patients and should be able to evade patient
immune response, abnormal expression of genes in iPSCs and their differentiated progeny has
been shown to induce immune responses in recipients [107]. A possible consequence of the
genetic and epigenetic instability, the inability of iPSCs to evade the innate immune response
of patients could lead to the rejection of iPSC grafts. Similarly, genomic and epigenetic
instability of iPSCs will frustrate efforts for developing iPSCs with specific function and
homing abilities. Hence more research is required before iPSCs suitable for use in patient
therapies will be available.
While current limitations of iPSC technology forestalls their direct use in patient therapy, the
versatility of iPSCs and their ease of derivation from patients has enabled their use in disease
modeling and in vitro drug screening. iPSCs can be derived from patients affected by various
diseases including LEOPARD syndrome, Schizophrenia, and X-linked adrenoleukodystrophy
and used in drug and functional tests [108, 109]. This has enabled the molecular pathways and
genetic mutations that cause these diseases to be studied in greater detail and led to the
development of new therapies for patients. Hence the discovery of iPSCs continues to
contribute to an improved knowledge of the underlying molecular mechanisms of various
diseases and catalyze the development of novel drugs for their treatment.
5. Embryonic stem cells
The first breakthrough technique for isolating and growing human ESCs in vitro was devel‐
oped at the University of Wisconsin-Madison in 1998 [110]. Since then, interest in developing
more efficient methods for deriving ESCs and research into potential therapies involving ESCs
has increased exponentially. ESC based therapies possess several natural advantages over
other stem cell therapies. Since ESCs are directly derived from the developing embryo, they
possess greater innate pluripotent capacity compared to most adult stem cells and could
potentially be used in a wider range of therapies. Additionally, while the pluripotent potential
and number of autogenic adult stem cells available may decline as patients age, ESC based
therapies do not share the same limitation and a potentially limitless source of stem cells can
be derived and cultured from blastocysts. Finally ESCs occur naturally in the inner cell mass
of blastocysts and can be easily derived with minimal genetic or epigenetic manipulation
unlike iPSCs.
The effectiveness and safety of ESCs therapies for treating various medical conditions includ‐
ing spinal cord injury, Stargardt's disease, and macular degeneration have been tested in
animal and human clinical trials [111-115]. These studies demonstrate that it is relatively easy
to obtain high quality and pathogen free human ESC cells, stimulate hESCs to form pure
populations of differentiated cells for transplantation, and obtain sufficient quantities of cells
for transplantation. Some studies of human ESC based transplants have also demonstrated
that ESC is potentially safe and can be conducted with minimal risk of teratoma formation and
graft rejection. The results of these animal and human ESC based clinical trials also indicate
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that human ESC transplantation can rescue animal models of retinal degeneration, Stargardt,
and spinal cord injury, and catalyze limited visual improvement in human macular degener‐
ation patients.
Despite these apparent advantages of human ESCs, its use in research and medical therapy
has been fairly controversial historically as the derivation of human ESC lines requires the
destruction of human embryos. Pro-life advocates have strongly opposed the destruction of
embryos for research on the basis that human life begins when a human egg cell is fertilized,
and the belief that human life is inviolable. More recently, these objections have been partially
overcome through the development of human ESC derivation procedures that do not require
embryo destruction [116] and the use of surplus frozen embryos from in vitro fertilization
clinics.
When evaluated against the four key milestones, it can be determined that while ESCs are
potentially safer than iPSCs, several key concerns continue to forestall their wider use in
human clinical trials. First while some studies of human ESC based transplants in animals and
humans have suggested that there is minimal risk of teratoma formation or uncontrolled
proliferation of transplanted cells, other studies contend that in vitro culture conditions can
result in potentially hazardous epigenetic modifications [117]. Second since ESC transplants
are allogeneic, there is a higher likelihood of immune rejection compared to autographs of
adult stem cells. Third ESC transplants potentially share similar location specificity limitations
as adult stem cell transplants. This limitation has to be addressed for the development of a
viable next generation stem cell therapy. Fourth since ESCs have a higher innate pluripotent
capacity than adult stem cells and iPSCs, it may be easier to obtain pure populations of
functionally specific and disease relevant transplant cells from ESC lines. In conclusion, while
more clinical trials will be required to assess the viability of ESC therapy, studies have indicated
that ESC therapy seems to offer a promising alternative for treating currently incurable
diseases.
6. The promise of transdifferentiation therapy
Transdifferentiation is the direct conversion of one cell type to another without the involve‐
ment of an intermediate pluripotent state. Transdifferentiation could be a viable alternative
therapy to stem cell therapies and relatively abundant adult somatic cells like fibroblasts and
adipocytes could be harvested from patients and directly converted by transdifferentiation to
neurons or cardiomyocytes before being used as autologous grafts in regenerative therapies.
Transdifferentiation is advantageous compared to adult stem cell therapy because cell grafts
could be designed specifically for each disease therapy resulting in improved functional and
positional specificity. Transdifferentiation is also advantageous compared to iPSC based
therapy because conversion to a desired cell type is a one step process requiring lesser
epigenetic modification, and is a more rapid and direct process than dedifferentiation to form
iPSCs followed by controlled differentiation into the desired cell type.
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Transdifferentiation can be a relatively spontaneous process such as the in vitro transdiffer‐
entiation of chick retinal cells to lens cells [118]. It can also be induced via the guided expression
of various molecular factors and genes. For example overexpression of Atoh1 can induce the
transdifferentiation of non-sensory supporting cells in the cochlea to auditory hair cells [67].
The expression of the microRNAs miR-9/9* and miR-124 can also induce the transdifferentia‐
tion of human fibroblasts to functional neurons [119]. However despite initial successes,
currently available methods for inducing transdifferentiation remain too inefficient in vivo
therapeutic purposes and further research is required to improve the process before it can be
considered as a viable therapeutic alternative.
7. Summary
The use of stem cells for therapeutic purposes will be increasingly widespread as improved
knowledge leads to the development of safer and more effective therapies. Stem cells derived
from patients have also been successfully used in disease modeling and therapy evaluation.
Further studies will enable the innate regenerative and immunomodulatory properties of stem
cells to be harnessed more effectively for treating a larger variety of diseases and injury. The
study and use of adult stem cells will continue to play a pivotal role in the ongoing search for
novel therapies due to their availability and safety, while further developments in iPSC and
ESC derivation and cultivation processes will be required before they can be used in therapies.
An improved understanding of genetic and epigenetic control continues to be a prerequisite
for the development of an ideal stem cell therapy. Finally further improvements in inducing
direct transdifferentiation of adult non-stem cells to the desired cell types may be an alternative
regenerative therapy that may circumvent the use of stem cells entirely.
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